RG6346 Phase 1 Proof-of-Concept Trial for Treatment of Chronic Hepatitis B Virus Infection
RG6346 is an investigational GalXC RNAi therapeutic candidate in Phase 1 for the treatment of chronic HBV infection.
The ongoing Phase 1 proof-of-concept trial in adults comprises three groups: Group A, a dose-ranging cohort with healthy volunteers, which was completed last year; Group B, composed of newly diagnosed participants not on any antiviral therapy who received a single dose of RG6346; and Group C, which includes participants concurrently receiving nucleoside analog therapy and four monthly doses of one of three dose levels of RG6346.
In the Phase 1 study, nine of 10 participants who received RG6346 and have completed the treatment period in Group C achieved ≥1.0 log10 IU/mL reduction in hepatitis B surface antigen (HBsAg) at Day 112 and continued in the extended follow-up period.
At Day 112, the mean reduction in HBsAg was 1.39 log10 IU/mL for the 1.5 mg/kg cohort, 1.80 log10 IU/mL for the 3.0 mg/kg cohort, and 1.84 log10 IU/mL for the 6.0 mg/kg cohort; two participants have not yet reached Day 112. Of these 10 participants who received RG6346 and completed the treatment period, six had HBsAg
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval